Sexually Transmitted Diseases:
Clinical and Virologic Response to Episodic Acyclovir for Genital Ulcers Among HIV-1 Seronegative, Herpes Simplex Virus Type 2 Seropositive African Women: A Randomized, Placebo-Controlled Trial
Baeten, Jared M. MD, PhD*†‡; Reid, Stewart E. MD§¶; Delany-Moretlwe, Sinead MD, PhD**; Hughes, James P. PhD††; Wang, Richard S. MS*; Wilcox, Ellen MSW, MPH*; Limbada, Mohammed MD¶; Akpomiemie, Godspower BPharm, MPH**; Corey, Lawrence MD†‡‡§§; Wald, Anna MD, MPH†‡‡‡§§; Celum, Connie MD, MPH*†‡
From the Departments of *Global Health, †Medicine, and ‡Epidemiology, University of Washington, Seattle, WA; §Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; ¶Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; **Wits Institute for Reproductive Health and HIV, School of Clinical Medicine, University of Witwatersrand, Johannesburg, South Africa; Departments of ††Biostatistics and ‡‡Laboratory Medicine, University of Washington, Seattle, WA; and §§Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA
The authors thank the study staff for their efforts, Dr. Meei-Li Huang and the University of Washington Virology Laboratory for HSV PCR testing, and the study participants for their time and dedication.
Supported by the US National Institutes of Health, National Institute of Allergy and Infectious Diseases (U01 AI52054 and P01 AI30731) and by the HIV Prevention Trials Network (HPTN) under Cooperative Agreement U01 AI46749, sponsored by the National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of Drug Abuse, National Institute of Mental Health, and Office of AIDS Research. L.C. has received consulting fees from AiCuris, which is developing treatments for HSV and cytomegalovirus infections, is listed as a coinventor on several patents describing antigens and epitopes to which T-cell responses to HSV-2 are directed (these proteins have the potential to be used in candidate vaccines against HSV), and has received fees for serving as the head of the scientific advisory board of Immune Design, including equity shares that are less than 1% ownership. A.W. has received consulting fees from AiCuris. A.W. and C.C. have received research grant support from GlaxoSmithKline. All other authors declare they have no known conflict of interest.
Correspondence: Jared Baeten, MD, PhD, University of Washington, Box 359927, 325 Ninth Ave, Seattle, WA 98104. E-mail: email@example.com.
Received for publication March 7, 2011, and accepted August 4, 2011.
In a randomized trial among African women with recurrent genital herpes, episodic acyclovir therapy resulted in modestly greater likelihood of lesion healing (hazard ratio [HR] = 1.48, P = 0.098; mean, 5.1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405).
The seroprevalence of herpes simplex virus type 2 (HSV-2), the primary etiology of genital herpes, exceeds 50% in African women, and HSV-2 increases a woman's HIV-1 acquisition risk by 3-fold.1 However, 2 randomized trials of acyclovir HSV-2 suppressive therapy (using a dose of 400 mg twice daily) failed to demonstrate protection against HIV-1 acquisition in high-risk, HIV-1 seronegative populations.2,3 In one of these trials (HIV Prevention Trials Network [HPTN] 039), among HIV-1 seronegative, HSV-2 seropositive men who have sex with men from the Americas and women from Africa, acyclovir reduced recurrent genital ulcers caused by HSV-2 by only 63%,3 lower than had been observed in previous studies of suppressive acyclovir from high-income settings,4 and the effect of acyclovir on frequency of genital ulcers and quantity of HSV-2 DNA in specimens collected from ulcers was less in the African participants than in those from the United States.5 One potential explanation for these findings is that African women with HSV-2 have diminished response to acyclovir therapy compared with populations from high-income settings. To test this hypothesis, we conducted a randomized, placebo-controlled trial of clinical and virologic response to episodic acyclovir therapy among HIV-1 uninfected, HSV-2 seropositive African women with recurrent genital herpes.
Study Design and Methods
Between January and December 2009, women from Johannesburg, South Africa, and Lusaka, Zambia, who had participated in HPTN 039 were invited to present to the HPTN 039 clinics if they had a new genital ulcer. These women, as well as others who had not participated in HPTN 039 but who presented with recurrent genital herpes during the recruitment period, were offered study participation. Women aged 18 to 50 years who were HIV-1 seronegative and HSV-2 seropositive were considered eligible; exclusion criteria included pregnancy or use of anti-HSV medications.
Women were randomly assigned in a 2:1 manner to acyclovir 400 mg orally 3 times daily for 5 days or matching placebo (Carlsbad Laboratories, San Diego, CA). This dosage and duration of acyclovir therapy is recommended by World Health Organization (WHO) and Centers for Disease Control for treatment of recurrent genital herpes6,7; however, episodic therapy for recurrent genital herpes had not been implemented as standard practice in South Africa or Zambia. Study clinicians and participants were blind to treatment assignments, and participants were counseled that episodic therapy is not curative for HSV-2 and that they may have been assigned to placebo. Women visited the study clinic daily for 5 days and then every other day for 8 days (for a total of 9 visits during 13 days of follow-up). A swab for HSV PCR from the largest lesion site was obtained at each visit. The protocol was approved by institutional review boards at the University of Washington and the collaborating study sites. Participants provided written informed consent. The trial was registered with ClinicalTrials.gov (NCT00808405).
HIV-1 serostatus was determined by paired rapid assay. HSV-2 serostatus was determined either by ELISA (Herpe-Select-2, Focus Technologies, Cypress, CA), performed at local laboratories and using an index value >3.4 to define a positive result,3 or, for women who had earlier participated in HPTN 039, by HSV Western blot.3 Swabs from the largest lesion site were tested in batch at the end of the study at the University of Washington by HSV DNA PCR, with a lower limit of HSV detection being 150 (2.18 log10) copies/swab.8
The primary study end point was time to complete healing of all genital lesions, defined as reepithelialization of skin. A predefined secondary end point was time to first negative HSV DNA PCR result. A sample size of 90 was estimated to provide 80% power to detect a 1.8-day difference between acyclovir and placebo in time to healing. Comparisons of acyclovir and placebo groups were calculated by an intent-to-treat approach using Cox proportional hazards regression and Kaplan-Meier estimation. Data were unblinded after all follow-up and laboratory testing were complete. Analyses were performed using SAS 9.2 and R v2.11.1.
Population and Results
Eighty-eight HIV-1 negative, HSV-2 seropositive women were randomized; 61 to the acyclovir arm and 27 to the placebo arm (Table 1). An additional 7 women who had genital lesions were enrolled but were subsequently determined to be HSV-2 seronegative and were excluded from all analyses. Most women (76/88, 86.4%) had participated in HPTN 039. The median number of lesions was 1 (interquartile range, 1–3), the median duration of genital symptoms was 1 day (interquartile range, 1–2), and >90% of lesions were in ulcerative or vesicular stages. At enrollment, 76 women (86.4%) had HSV DNA detected by PCR.
Eighty-five women (96.6%, 59 acyclovir/26 placebo) completed the 13-day follow-up, and, excluding days that participants were unable to attend because of weekend and holiday site closures, 596 of 610 (97.7%) scheduled follow-up visits were attended (410/423 [96.9%] acyclovir, 186/187 [99.5%] placebo). Three participants (2 acyclovir, 1 placebo) reported missing 1 dose of study medication during the 5 days of 3 times daily study medication. By day 13, all participants had achieved complete healing of all genital lesions.
The time to reaching the primary (healing of all lesions) and secondary (first negative HSV DNA PCR) end points was shorter for those randomized to acyclovir compared with placebo (Fig. 1), although the primary end point did not achieve statistical significance. By Cox proportional hazards analysis, acyclovir resulted in 1.48-fold (P = 0.098; mean, 5.1 vs. 6.0 days) greater likelihood of healing of all lesions and 1.88-fold (P = 0.008; mean, 3.0 vs. 5.0 days) greater likelihood of cessation of HSV shedding. The magnitude of these effects was similar among the subset of women whose genital swab was HSV DNA PCR positive at the enrollment visit and was modestly greater among those whose genital lesion was in vesicular stage at enrollment.
In this randomized, double-blind, placebo-controlled trial, with frequent measurements of clinical and virologic response during 13 days of follow-up, we demonstrated that a standard 5-day course of oral acyclovir modestly shortens time to lesion healing and to cessation of HSV-2 shedding among HIV-1 seronegative, HSV-2 seropositive African women with recurrent genital herpes. Our results, including a greater effect on HSV shedding than clinical healing, are consistent with findings from studies from high-income settings of treatment of recurrent genital herpes, which found that acyclovir improved healing and time to cessation of shedding by 1 to 2 days.9–11 The clinical and virologic course in the placebo arm was compatible with the natural history of genital herpes in other populations, and, as would be expected for an immunocompetent population, all lesions were healed by 13 days.
Our results argue that diminished virologic response to acyclovir among African women does not explain the failure of HSV-2 suppressive therapy to prevent HIV-1 acquisition in 2 clinical trials.2,3 Lack of adherence to acyclovir has been proposed as an alternative explanation, but adherence was high in HPTN 039.3 One intriguing hypothesis for the failure of HSV-2 suppressive therapy to reduce HIV-1 risk is that HSV-2 reactivation is associated with a dense and persistent infiltration of HIV-1 receptor cells in the genital mucosa,12 suggesting that highly potent and durable HSV-2 suppressive therapies might be needed to intervene with HSV-2 to reduce HIV-1 risk.
Not all studies from Africa have found an effect of acyclovir on healing of genital herpes lesions. Potential explanations that may account for these differences include that most previous trials were primarily among HIV-1-infected persons, episodic treatment was started later (after an average of 1 week of symptoms), and follow-up schedules in those studies may have been too infrequent to detect the 1- to 2-day benefit observed in the current study.13–15 However, among South African men with HIV-1 who presented early with genital ulcers, acyclovir improved healing by a median of 3 days and reduced HIV-1 shedding.13 Most women in our study had previously participated in HPTN 039 and were aware of their HSV-2 serostatus; they presented early, with a median of 1 day of symptoms and >90% of lesions in vesicular or ulcerative stages. This is encouraging in terms of the value of counseling HSV-2 seropositive persons about clinical manifestations of genital herpes and the importance of early initiation of episodic acyclovir or the possibility of suppressive acyclovir, where available.
In summary, we found that HSV-2 seropositive, HIV-1 uninfected African women with recurrent genital herpes had a similar virologic and clinical response to acyclovir as was seen previously in immunocompetent populations from North America and Europe. Genital herpes account for the majority of genital ulcer disease in sub-Saharan Africa, where diagnostic tests for HSV are rarely available. Although acyclovir is available as a generic preparation, is on the WHO List of Essential Drugs for developing countries, and is recommended by WHO for syndromic management of genital ulcer disease,6 cost and availability have limited its use in Africa.16 Our results demonstrate that there are modest clinical and virologic benefits of acyclovir for recurrent genital herpes when initiated promptly after lesions develop, emphasizing its potential when included as part of first-line syndromic management of genital ulcers.
1.Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73–83.
2.Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560–1571.
3.Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomized, double-blind, placebo-controlled trial. Lancet 2008; 371:2109–2119.
4.Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190:1374–1381.
5.Fuchs J, Celum C, Wang J, et al. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. J Infect Dis 2010; 201:1164–1168.
6.World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva, Switzerland: World Health Organization, 2003.
7.Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. Morb Mortal Wkly Rep 2006; 55:1–94.
8.Jerome KR, Huang ML, Wald A, et al. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002; 40:2609–2611.
9.Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982; 2:571–573.
10.Bryson YJ, Dillon M, Lovett M, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med 1983; 308:916–921.
11.Bavaro JB, Drolette L, Koelle DM, et al. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Sex Transm Dis 2008; 35:383–386.
12.Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886–892.
13.Paz-Bailey G, Sternberg M, Puren AJ, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: A randomized, controlled trial. J Infect Dis 2009; 200:1039–1049.
14.Phiri S, Hoffman IF, Weiss HA, et al. Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi. Sex Transm Infect 2010; 86:345–352.
15.Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: A randomized placebo-controlled trial. J Infect Dis 2009; 200:216–226.
16.Corbell C, Stergachis A, Ndowa F, et al. Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries. Sex Transm Dis 2010; 37:488–493.
© Copyright 2012 American Sexually Transmitted Diseases Association